Buy RARE by Dec 3, 2026.

**One failed Phase 3 trial erased roughly 44% of Ultragenyx’s share price in a single session.** But the company did not wake up on September 3 as an empty biotech shell. It still has a growing commercial business, a newly approved gene therapy, and a second gene-therapy FDA decision scheduled for September 19. The question is whether the market has correctly repriced a damaged platform—or thrown away too much with the failed Angelman program.